{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:24:25Z","timestamp":1792110265037,"version":"4.4.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To evaluate the cost effectiveness of menopausal hormone therapy (MHT) based on the risk\u2013benefit profiles of current MHT formulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>We used a Markov model to examine the cost effectiveness of MHT for hypothetical 50-year-old women with vasomotor symptoms compared with transdermal estradiol (E2) alone for patients without a uterus and transdermal E2 in combination with micronized progesterone for patients with a uterus, assuming 5 years of use. Using a health system perspective, we expressed the effectiveness in quality-adjusted life years (QALYs), and the willingness-to-pay threshold was set to $100,000 per QALY gained. We derived probabilities, cost data, and utilities from the literature and estimated the incremental cost-effectiveness ratios between the MHT and no MHT strategies as our primary outcome. Secondary outcomes included the number of cases of cardiovascular disease, breast cancer, colon cancer, and hip fracture and the number of deaths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Use of MHT demonstrated absolute dominance over not using MHT for both the E2 and E2+micronized progesterone arms. Per 10,000 patients over a lifetime, E2 compared with no MHT was $135,396,560 less expensive, resulted in a gain of 33,196 QALYs, and was associated with 259 fewer cases of atherosclerotic cardiovascular disease (ASCVD), 105 fewer colon cancer cases, 87 more breast cancer cases, 181 fewer hip fractures, and 647 fewer deaths. Micronized progesterone compared with no MHT was $127,738,990 less expensive, resulted in a gain of 33,083 QALYs, and was associated with 285 fewer cases of ASCVD, 18 more colon cancer cases, 46 more breast cancer cases, 183 fewer hip fractures, and 615 fewer deaths. Sensitivity analysis showed that variables related to ASCVD had the most effect on the model. Probabilistic sensitivity analysis revealed absolute dominance for both MHT strategies at all willingness-to-pay thresholds up to $200,000.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Our model suggests that MHT is cost effective for typical patients experiencing menopausal symptoms with initiation of MHT at age 50 years and use for 5 years. The reduction in ASCVD risk by MHT is the largest driver of cost effectiveness in the model.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000006404","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T21:00:24Z","timestamp":1786654824000},"page":"693-702","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Cost-Effectiveness Analysis of Menopausal Hormone Therapy"],"prefix":"10.1097","volume":"148","author":[{"given":"Elizabeth","family":"Gill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Shvartsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1615-4584","authenticated-orcid":false,"given":"Jill","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"R1-20261015","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1089\/15409990260363661","article-title":"Quality of life and menopause: the role of estrogen","volume":"11","author":"Freedman","year":"2002","journal-title":"J Womens Health (Larchmt)"},{"key":"R2-20261015","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"R3-20261015","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/AOG.0000000000000469","article-title":"Trends of postmenopausal estrogen plus progestin prevalence in the United States between 1970 and 2010","volume":"124","author":"Jewett","year":"2014","journal-title":"Obstet Gynecol"},{"key":"R4-20261015","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American Menopause Society","volume":"29","year":"2022","journal-title":"Menopause"},{"key":"R5-20261015","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/AOG.0000000000004723","article-title":"Menopausal hormone therapy formulation and breast cancer risk","volume":"139","author":"Abenhaim","year":"2022","journal-title":"Obstet Gynecol"},{"key":"R6-20261015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/13697137.2017.1421925","article-title":"The impact of micronized progesterone on breast cancer risk: a systematic review","volume":"21","author":"Stute","year":"2018","journal-title":"Climacteric"},{"key":"R7-20261015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/13696998.2023.2289297","article-title":"Evaluating the cost utility of estradiol plus dydrogesterone for the treatment of menopausal women in China","volume":"27","author":"Tamlyn Anne","year":"2024","journal-title":"J Med Econ"},{"key":"R8-20261015","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12913-017-2227-y","article-title":"Menopausal hormone therapy: a systematic review of cost-effectiveness evaluations","volume":"17","author":"Velentzis","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"R9-20261015","doi-asserted-by":"crossref","first-page":"dgaa623","DOI":"10.1210\/clinem\/dgaa623","article-title":"Approach to managing a postmenopausal patient","volume":"105","author":"Santen","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R10-20261015","doi-asserted-by":"crossref","DOI":"10.1111\/1471-0528.70023","article-title":"Women's and health care professionals' experiences of discontinuing hormone replacement therapy (HRT): a systematic review","author":"Bunnewell","year":"2025","journal-title":"BJOG"},{"key":"R11-20261015","doi-asserted-by":"crossref","first-page":"k4810","DOI":"10.1136\/bmj.k4810","article-title":"Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"364","author":"Vinogradova","year":"2019","journal-title":"BMJ"},{"key":"R13-20261015","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12933-024-02324-w","article-title":"Trends in direct health care costs among US adults with atherosclerotic cardiovascular disease with and without diabetes","volume":"23","author":"Shah","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"suppl 1","key":"R14-20261015","first-page":"S1","article-title":"Economic burden of atherosclerotic cardiovascular disease and specific events in Ontario, Canada [abstract]","volume":"23","author":"Rogoza","year":"2020","journal-title":"Value Health"},{"key":"R15-20261015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010-2020","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"R16-20261015","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1359\/jbmr.090523","article-title":"Health care expenditures associated with skeletal fractures among Medicare beneficiaries, 1999-2005","volume":"24","author":"Kilgore","year":"2009","journal-title":"J Bone Miner Res"},{"key":"R20-20261015","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.numecd.2010.02.001","article-title":"Cardiovascular diseases in American women","volume":"20","author":"Zhang","year":"2010","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R22-20261015","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jama.2009.1462","article-title":"Incidence and mortality of hip fractures in the United States","volume":"302","author":"Brauer","year":"2009","journal-title":"JAMA"},{"key":"R23-20261015","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/bjc.2016.314","article-title":"Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study","volume":"115","author":"Colzani","year":"2016","journal-title":"Br J Cancer"},{"key":"R24-20261015","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2666-7568(23)00285-4","article-title":"Risk of fractures in half a million survivors of 20 cancers: a population-based matched cohort study using linked English electronic health records","volume":"5","author":"Buzasi","year":"2024","journal-title":"Lancet Healthy Longev"},{"key":"R25-20261015","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","article-title":"One-year cardiovascular event rates in outpatients with atherothrombosis","volume":"297","author":"Steg","year":"2007","journal-title":"JAMA"},{"key":"R27-20261015","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/17453674.2019.1680485","article-title":"Postoperative mortality after a hip fracture over a 15-year period in Denmark: a national register study","volume":"91","author":"Gundel","year":"2020","journal-title":"Acta Orthop"},{"key":"R29-20261015","first-page":"CD002229","article-title":"Hormone therapy for preventing cardiovascular disease in post-menopausal women","author":"Boardman","year":"2015","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"R30-20261015","doi-asserted-by":"crossref","first-page":"20631","DOI":"10.1038\/s41598-020-77534-9","article-title":"A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"key":"R31-20261015","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1001\/jama.291.18.2212","article-title":"Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women","volume":"291","author":"Banks","year":"2004","journal-title":"JAMA"},{"key":"R32-20261015","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJM199706193362501","article-title":"Postmenopausal hormone therapy and mortality","volume":"336","author":"Grodstein","year":"1997","journal-title":"N Engl J Med"},{"key":"R33-20261015","doi-asserted-by":"crossref","first-page":"e085998","DOI":"10.1136\/bmj-2025-085998","article-title":"Menopausal hormone therapy and long term mortality: nationwide, register based cohort study","volume":"392","author":"Mikkelsen","year":"2026","journal-title":"BMJ"},{"key":"R34-20261015","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/apt.16362","article-title":"Menopausal hormone therapies and risk of colorectal cancer: a Swedish matched-cohort study","volume":"53","author":"Liu","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"R35-20261015","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s11136-020-02650-y","article-title":"US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples","volume":"30","author":"Jiang","year":"2021","journal-title":"Qual Life Res"},{"key":"R36-20261015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1017\/S0266462305050609","article-title":"Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial","volume":"21","author":"Zethraeus","year":"2005","journal-title":"Int J Technol Assess Health Care"},{"key":"R37-20261015","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1089\/jwh.2008.1246","article-title":"Cost-effectiveness of hormone therapy in the United States","volume":"18","author":"Lekander","year":"2009","journal-title":"J Womens Health (Larchmt)"},{"key":"R38-20261015","first-page":"CD002978","article-title":"Oral oestrogen and combined oestrogen\/progestogen therapy versus placebo for hot flushes","volume":"4","author":"Maclennan","year":"2004","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"R39-20261015","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"R41-20261015","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"R42-20261015","doi-asserted-by":"crossref","first-page":"6356","DOI":"10.1016\/j.vaccine.2021.09.044","article-title":"Optimizing immunization schedules in endemic cholera regions: cost-effectiveness assessment of vaccination strategies for cholera control in Bangladesh","volume":"39","author":"Zeng","year":"2021","journal-title":"Vaccine"},{"key":"R43-20261015","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1161\/CIR.0000000000000912","article-title":"Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association","volume":"142","author":"El Khoudary","year":"2020","journal-title":"Circulation"},{"key":"R44-20261015","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1089\/jwh.2015.5556","article-title":"Perimenopause: from research to practice","volume":"25","author":"Santoro","year":"2016","journal-title":"J Womens Health (Larchmt)"},{"key":"R45-20261015","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1001\/jama.2015.12783","article-title":"Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society","volume":"314","author":"Oeffinger","year":"2015","journal-title":"JAMA"},{"key":"R46-20261015","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"R47-20261015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/jama.2020.9482","article-title":"Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials","volume":"324","author":"Chlebowski","year":"2020","journal-title":"JAMA"},{"key":"R48-20261015","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","article-title":"An introduction to Markov modelling for economic evaluation","volume":"13","author":"Briggs","year":"1998","journal-title":"Pharmacoeconomics"},{"key":"R49-20261015","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: a practical guide","volume":"13","author":"Sonnenberg","year":"1993","journal-title":"Med Decis Making"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:02:08Z","timestamp":1792069328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000006404","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"2026-03-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}